Bone Biologics Corp Files S-1 for Potential Public Offering

TL;DR

<b>Bone Biologics Corp has filed an S-1 registration statement, signaling potential entry into the public markets.</b>

AI Summary

Bone Biologics Corp (BBLGW) filed a IPO Registration (S-1) with the SEC on January 30, 2024. Bone Biologics Corp filed an S-1 registration statement on January 30, 2024. The company is incorporated in Delaware (DE). Its principal business address is located in Burlington, MA. The filing indicates a fiscal year end of December 31st. The company was formerly known as AFH Acquisition X, Inc. before a name change in 2007.

Why It Matters

For investors and stakeholders tracking Bone Biologics Corp, this filing contains several important signals. This S-1 filing is a prerequisite for Bone Biologics Corp to conduct an initial public offering (IPO) or other public securities offering, potentially providing the company with significant capital for growth and operations. The filing provides detailed financial information and business descriptions, offering investors a transparent view of the company's current standing and future prospects.

Risk Assessment

Risk Level: — Bone Biologics Corp shows moderate risk based on this filing. The filing is an S-1, which is a preliminary registration statement for a potential public offering and does not contain detailed operational or financial performance data beyond what is typically included in such initial filings.

Analyst Insight

Monitor for subsequent amendments to the S-1 filing, which will provide more specific details on the offering size, pricing, and use of proceeds.

Key Numbers

• S-1 — Form Type (Type of registration statement filed)
• 2024-01-30 — Filing Date (Date the S-1 was filed)
• 1231 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• Bone Biologics Corp (company) — Filer of the S-1 registration statement
• AFH Acquisition X, Inc. (company) — Former name of Bone Biologics Corp
• DE (location) — State of incorporation
• MA (location) — State of business address
• 20240130 (date) — Filing date

Forward-Looking Statements

• Bone Biologics Corp. will successfully complete a public offering to raise capital. (Bone Biologics Corp.) — medium confidence, target: 2024-12-31
• The company's stock price will experience short-term volatility due to potential dilution from the offering. (Bone Biologics Corp. stock) — high confidence, target: 2024-06-30

FAQ

Industry Context

The company operates in the orthopedic, prosthetic & surgical appliances & supplies industry.

Regulatory Implications

The S-1 filing is a regulatory document required by the SEC for companies intending to offer securities to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed business operations, risk factors, and financial projections.
2. Track subsequent SEC filings (amendments to S-1, prospectuses) for updates on the offering.
3. Analyze the company's market and competitive landscape within the orthopedic device sector.

Key Dates

• 2024-01-30: S-1 Filing — Indicates intent for public offering

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of this type to compare against for the purpose of 'vs last filing'.

Key Financial Figures

• $0.001 — up to shares of common stock, par value $0.001 per share ("common stock"), together wi
• $0 — ur common stock at an exercise price of $0.001, which we refer to as the "pre-fund
• $35,000 — accountable expenses in an amount up to $35,000, legal fees and expenses in the amount
• $100,000 — ees and expenses in the amount of up to $100,000, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t

Filing Documents

• forms-1.htm (S-1) — 2772KB
• ex4-2.htm (EX-4.2) — 229KB
• ex4-5.htm (EX-4.5) — 137KB
• ex4-6.htm (EX-4.6) — 134KB
• ex4-7.htm (EX-4.7) — 147KB
• ex10-2.htm (EX-10.2) — 87KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 21KB
• forms-1_001.jpg (GRAPHIC) — 7KB
• 0001493152-24-004349.txt (&nbsp;) — 9308KB
• bblg-20230930.xsd (EX-101.SCH) — 48KB
• bblg-20230930_cal.xml (EX-101.CAL) — 36KB
• bblg-20230930_def.xml (EX-101.DEF) — 198KB
• bblg-20230930_lab.xml (EX-101.LAB) — 364KB
• bblg-20230930_pre.xml (EX-101.PRE) — 289KB
• forms-1_htm.xml (XML) — 1386KB

DILUTION

DILUTION 36 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 37

BUSINESS

BUSINESS 42 MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 51 MANAGEMENT 52 EXECUTIVE AND DIRECTOR COMPENSATION 55 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 59

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 60

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 61 PLAN OF DISTRIBUTION 65 LEGAL MATTERS 67 EXPERTS 67 WHERE YOU CAN FIND MORE INFORMATION 67

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 iii ABOUT THIS PROSPECTUS We have not, and the placement agent has not, authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission (the "SEC"). We do not, and the placement agent and its affiliates do not, take any responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. This prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty, including those discussed in "Risk Factors." We caution you not to give undue weight to such projections, assumptions and estimates. Further, industry and general publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that these publications, studies and surveys are reliable, we have not independently verified the data contained in them. In addition, while we believe that the results and est

View Full Filing

View this S-1 filing on SEC EDGAR